Rick Bangs, a bladder cancer survivor celebrating his Neobladder's 10th birthday gave a real and moving talk discussing the reality of financial toxicity in bladder cancer patients. Financial barriers are an increasing concern in cancer care with the development of new cancer therapies, investigations and increasing patient visits.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Banks defined patient and caregiver solutions. He urged patients to ask financial questions, get estimates upfront, include outcomes and side effects in discussions, and to shop around amongst different providers as cost is highly variable amongst them. Physician based financial solutions to advocacy included encouraging the physician to be a catalyst for further dialogue and solutions, and to lobby payers to reimburse treatments that add real value to the portfolio and abandon treatments that do not earn their place in treatment. He clearly outlines that solutions will require collaboration amongst patients, physicians, industry, advocacy network, insurance companies, research design and government.
Bangs offered a simple message that is critically important to the patients’ well being and a goal that should be achievable through transparency and communication.
Presented By: Rick Bangs, Patient Advocate
Written by: Michael J Metcalfe, MD. Fellow of Urologic Oncology Urology, MD Anderson Cancer Center, Houston TX
Ashish M. Kamat, MD, MBBS, FACS
President, International Bladder Cancer Network
Chair, Society of Immunotherapy for Cancer (SITC), BCTF
Director of Urologic Oncology Fellowship
Professor of Urology
Attending Surgeon, Division of Surgery
The University of Texas, MD Anderson Cancer Center